News releases

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for building on the success of its biosimilar switching program and called on other provinces to implement similar programs.

The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for announcing a program in which patients taking originator biologic drugs will be “switched” or transitioned by their clinicians to a biosimilar biologic drug within a six-month period.

Biosimilars Canada, the national association representing Canada’s biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform.

Read more

The convergence of regulatory requirements is a top priority for sponsors of biosimilar medicines as single global development programs are typical given the high R&D costs for these complex products.